Acipimox is a nicotinic acid derivative primarily indicated for the treatment of Fredrickson type IIb and type IV hyperlipoproteinemia by helping to modulate lipid levels. This category provides essential… Read more









Acipimox is a nicotinic acid derivative primarily indicated for the treatment of Fredrickson type IIb and type IV hyperlipoproteinemia by helping to modulate lipid levels. This category provides essential materials for pharmaceutical research and development, including the Acipimox parent compound, its pharmacopeial and non-pharmacopeial impurities, and stable isotope-labelled analogues such as Acipimox-d4. Laboratories rely on these high-quality reference standards and related compounds to perform rigorous impurity profiling and method validation. Stable isotope-labelled compounds are particularly valuable as internal standards in mass spectrometry-based assays, ensuring accuracy and precision during routine quality control procedures. By utilizing these characterized substances, analysts can effectively identify and quantify potential degradation products and process-related impurities, supporting the safety and regulatory compliance of drug formulations throughout the pharmaceutical lifecycle.